Market Cap | 5.35M | P/E | - | EPS this Y | 98.30% | Ern Qtrly Grth | - |
Income | -37.71M | Forward P/E | -0.40 | EPS next Y | -5.60% | 50D Avg Chg | -55.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -97.00% |
Dividend | N/A | Price/Book | 0.40 | EPS next 5Y | - | 52W High Chg | -100.00% |
Recommedations | 2.00 | Quick Ratio | 0.02 | Shares Outstanding | 4.85M | 52W Low Chg | 5.00% |
Insider Own | 0.00% | ROA | -128.31% | Shares Float | 4.85M | Beta | 0.98 |
Inst Own | - | ROE | - | Shares Shorted/Prior | 106.97K/46.36K | Price | 1.89 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 989,690 | Target Price | 500.00 |
Oper. Margin | - | Earnings Date | Nov 7 | Volume | 114,133 | Change | -2.58% |
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
HC Wainwright & Co. | Neutral | Aug 15, 24 |
HC Wainwright & Co. | Neutral | Jun 24, 24 |
HC Wainwright & Co. | Neutral | May 16, 24 |
HC Wainwright & Co. | Buy | Apr 2, 24 |
Roth MKM | Buy | Mar 27, 24 |
Roth MKM | Buy | Feb 5, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
GOLDMAN SACHS GROUP INC | 10% Owner 10% Owner | Nov 08 | Sell | 0.71 | 72,874 | 51,741 | 397,954 | 11/13/23 |